Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prospective Study on the Survival of HCC Patients Treated with Transcatheter Arterial Lipiodol Chemoembolization

  • Mao, Ying-Min (Department of Radiology, Zhejiang Provincial People's Hospital) ;
  • Luo, Zu-Yan (Department of Radiology, Zhejiang Provincial People's Hospital) ;
  • Li, Bo (Department of Radiology, Zhejiang Provincial People's Hospital) ;
  • Hu, Ting-Yang (Department of Radiology, Zhejiang Provincial People's Hospital)
  • Published : 2012.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: Tanscatheter arterial embolization irrespective of with or without an anticancer agent and lipiodol has been controversial with regard to survival benefit. Therefore, we conducted a prospective study to analyze the effect of transcatheter arterial lipiodol chemoembolization (TACE) on the survival of HCC. Methods: A prospective study was conducted, and a total of 326 patients with primary liver cancer who were newly diagnosed were collected from January 2004 to January 2005 in Zhejiang Provincial People's Hospital of China. A univariate Cox's regression analysis was used to assess the survival of the HCC cases receiving TACE. Results: The duration of follow-up for the HCC patients treated with TACE ranged from 3 months to 60 months. For the overall patients, survival rate at 5 years was 42%. Both HBV Ag and HCV Ab positive patients showed significantly low survival rate at 5 years. The multivariate analysis revealed The IV TNM stage was related to an heavy increased risk of death of HCC patients, and Child C grade group showed a significant moderate increased risk. Conclusion: Our study showed TACE is associated with a better prognosis of HCC patients, and the HBV infection, TNM stage, Child-Pugh grade and number of TACE may influence the survival probability. Further TACE studies should be assess the quality of life of HCC patients, so as to provide more information for treatment of HCC.

Keywords

References

  1. Bruix J, Castells A,Montanya X, et al (1994). Phase II study of transarterial embolisation in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology, 20, 643-50. https://doi.org/10.1002/hep.1840200315
  2. Chen MF, Hwang TL, Jeng LB, et al (1994). Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg, 129, 738-42. https://doi.org/10.1001/archsurg.1994.01420310070012
  3. Chin PL, Chu DZJ, Clarke KG, et al (1999). Ethnic differences in the behavior of hepatocellular carcinoma. Cancer, 85, 1931-6. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9%3C1931::AID-CNCR8%3E3.0.CO;2-O
  4. Choi BI, Kim HC, Han JK, et al (1992). Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathological findings. Radiology, 182, 709-13. https://doi.org/10.1148/radiology.182.3.1311116
  5. Doyon DMA, Jourde AM, Regensberg C, et al (1974). L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol, 17, 593-603.
  6. Farinati F, De Maria N, Marafin C, et al (1996). Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci, 41, 2332-9. https://doi.org/10.1007/BF02100123
  7. Huppert PE, Geissier F, Duda SH, et al (1994). Chemoembolisation deshepatozellularen karzinom: computertomographische befunde unf klinische resultate bei prospektiv repetitiver therapie. Rofo Forschr Geb Rontgenstr Neuen Bildgeb Verfahr, 160, 425-32. https://doi.org/10.1055/s-2008-1032453
  8. Ikeda K, Kumada H, Saitoh S, et al (1991). Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the Cox proportional hazard model. Cancer, 68, 2150-4. https://doi.org/10.1002/1097-0142(19911115)68:10<2150::AID-CNCR2820681011>3.0.CO;2-F
  9. Imamura H, Matsuyama Y, Tanaka E, et al (2003). Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol, 38, 200-7.
  10. Koda M, Murawaki Y, Mitsuda A, et al (2000). Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer, 88, 529-37. https://doi.org/10.1002/(SICI)1097-0142(20000201)88:3<529::AID-CNCR6>3.0.CO;2-M
  11. Konno T, Maeda H, Iwai K, et al (1983). Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol, 19, 1053-65. https://doi.org/10.1016/0277-5379(83)90028-7
  12. Lee HS, Kim KM, Yoon JH, et al (2002). Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol, 20, 4459-65. https://doi.org/10.1200/JCO.2002.02.013
  13. Llovet JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17. https://doi.org/10.1016/S0140-6736(03)14964-1
  14. Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet, 359, 1734-9. https://doi.org/10.1016/S0140-6736(02)08649-X
  15. Lo CM, Ngan H, Tso WK, et al (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 35, 1164-71. https://doi.org/10.1053/jhep.2002.33156
  16. Lopez RR, Pan SH, Hoffman L, et al (2002). Comparison of transarterial chemoembolization in patients with unresectable diffuse vs. focal hepatocellular carcinoma. Arch Surg, 137, 653-8. https://doi.org/10.1001/archsurg.137.6.653
  17. Mondazzi L, Bottelli R, Brambilla G, et al (1994). Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology, 19, 1115-23. https://doi.org/10.1002/hep.1840190508
  18. Nakamura H, Tanaka T, Hori S, et al (1983). Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology, 147, 401-5. https://doi.org/10.1148/radiology.147.2.6300959
  19. Okuda K, Obata H, Ohtsuki T, et al (1984). Prognosis of primary hepatocellular carcinoma. Hepatology, 4, S3-6. https://doi.org/10.1002/hep.1840040703
  20. Raoul JL, Hersebach D, Bretagne JF, et al (1992). Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmokinetics of doxorubicin. Cancer, 70, 585-90. https://doi.org/10.1002/1097-0142(19920801)70:3<585::AID-CNCR2820700308>3.0.CO;2-#
  21. Savastano S, Miotto D, Casarrubea G, et al (1999). Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol, 28, 334-40. https://doi.org/10.1097/00004836-199906000-00010
  22. Solomon B, Soulen MC, Baum RA, et al (1999). Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. J Vasc Interv Radiol, 10, 793-8. https://doi.org/10.1016/S1051-0443(99)70117-X

Cited by

  1. Experiences of Family of Patient with Newly Diagnosed Advanced Terminal Stage Hepatocellular Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4655
  2. Drainage Alone or Combined with Anti-tumor Therapy for Treatment of Obstructive Jaundice Caused by Recurrence and Metastasis after Primary Tumor Resection vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2681
  3. Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3651
  4. In Vivo Evaluation of Feeding Arteries of Tumors in Dorsal Sector of the Liver vol.12, pp.2, 2015, https://doi.org/10.5812/iranjradiol.18801
  5. Expression of Epidermal Growth Factor-like Domain 7 is Increased by Transcatheter Arterial Embolization of Liver Tumors vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1191
  6. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma vol.94, pp.37, 2015, https://doi.org/10.1097/MD.0000000000001431